Pear Therapeutics

Deals

(Photo by Klaus Vedfelt/Getty Images)

By  Laura Lovett 11:56 am April 6, 2021
Digital therapeutics company Pear Therapeutics is looking to integrate digital biomarkers, machine learning algorithms and sensor-based technologies into its platform thanks to new licensing deals and partnerships. The Boston-based DTx company has inked collaboration deals with Empatica and etectRx, as well as licensing tech from KeyWise. Specifically, Pear's collaboration with Empatica will...
By  Dave Muoio 01:12 pm March 1, 2021
Prescription digital therapeutics company Pear Therapeutics announced this morning that it has added $20 million more to an $80 million Series D funding round announced back in December. The company did not name any participants of this second closing, but highlighted "a leading national Integrated Delivery Network" as the source of the $20 million and the digital therapeutics company's newest...
By  Dave Muoio 03:50 pm February 12, 2021
Digital therapeutics have been plodding on a steady path toward acceptance within healthcare, but the modality reached new heights during a year of unprecedented adoption for digital health technologies. More and more software-based treatments are picking up regulatory approvals – including three De Novo clearances in 2020 alone – while the ongoing COVID-19 pandemic has exposed more consumers,...

Photo by Douglas Sacha (Getty)

By  Alexandra Mullin and Ian Chiang 01:16 pm January 29, 2021
The alarming scale of the opioid use disorder (OUD) epidemic has resulted in unprecedented human and economic devastation, and there is significant opportunity for digital tools to alter the gold standard of care to one that is ongoing and on-demand. The epidemic has only worsened since the onset of COVID-19, given heightened economic instability, social isolation, disruption to transportation...
etectRx
By  Laura Lovett 03:03 pm January 15, 2021
Earlier this week DTx company Pear Therapeutics inked a deal with adherence tool etectRx to potentially develop a product that combines the former’s digital therapeutics with a digital pill offering. As part of the deal the two companies will meet quarterly to discuss potential collaborations with the pharma industry. “Here we are talking about how can we bring this to pharma... we are going to...
The current version of PEAR-004, the company's digital therapeutic for schizophrenia
By  Jonah Comstock 01:59 pm January 13, 2021
Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture. The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the...
By  Laura Lovett 02:41 pm December 29, 2020
The life science world has continued to deepen its interest in the digital space. While the mainstream life science news of the year was research on the coronavirus vaccine, when it came to digital the industries efforts were more varied. We saw new partnerships between pharma and digital health around topics such as respiration health, cardiovascular conditions and real-world data.  This year we...
Three reSET app screen examples
By  Dave Muoio 12:14 pm December 8, 2020
Prescription digital therapeutics startup Pear Therapeutics announced an $80 million Series D round this morning headed by SoftBank Vision Fund 2. The raise included funds from new backers Forth Management, Pilot House, Sarissa Capital, Shanda Group and QUAD Investment Management, as well as from returning investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis,...
 The cognitive behavioral therapy for insomnia program is designed to be an end-to-end virtual experience.
By  Mallory Hackett 11:18 am November 17, 2020
Pear Therapeutics announced today the availability of its prescription digital therapeutic for chronic insomnia in adults over the age of 22, called Somryst. Somryst uses cognitive behavioral therapy for insomnia (CBTi) to train the brain and body to sleep. Over the course of the patient’s program, the therapy guides them through lessons and challenges, including algorithm-driven sleep...
By  Dave Muoio 01:55 pm November 5, 2020
A recently published review of real-world claims data suggests that opioid use disorder patients prescribed Pear Therapeutics' reSET-O digital therapeutic, alongside pharmacotherapy, had fewer clinical encounters and subsequently decreased medical costs over a six-month period. The study was funded by Pear, coauthored by a Pear employee and published in the journal Expert Review of...